253 related articles for article (PubMed ID: 30244615)
1. Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging.
Duda P; Wiśniewski J; Wójtowicz T; Wójcicka O; Jaśkiewicz M; Drulis-Fajdasz D; Rakus D; McCubrey JA; Gizak A
Expert Opin Ther Targets; 2018 Oct; 22(10):833-848. PubMed ID: 30244615
[TBL] [Abstract][Full Text] [Related]
2. GSK3 inhibitors and disease.
Hernández F; Nido JD; Avila J; Villanueva N
Mini Rev Med Chem; 2009 Aug; 9(9):1024-9. PubMed ID: 19689399
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
Cole AR
FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase 3: a drug target for CNS therapies.
Bhat RV; Budd Haeberlein SL; Avila J
J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
[TBL] [Abstract][Full Text] [Related]
5. GSK3 in Alzheimer's disease: mind the isoforms.
Ma T
J Alzheimers Dis; 2014; 39(4):707-10. PubMed ID: 24254703
[TBL] [Abstract][Full Text] [Related]
6. Identification of glia phenotype modulators based on select glial function regulatory signaling pathways.
Lee SH; Suk K
Expert Opin Drug Discov; 2018 Jul; 13(7):627-641. PubMed ID: 29676181
[TBL] [Abstract][Full Text] [Related]
7. The GSK3 beta signaling cascade and neurodegenerative disease.
Kaytor MD; Orr HT
Curr Opin Neurobiol; 2002 Jun; 12(3):275-8. PubMed ID: 12049933
[TBL] [Abstract][Full Text] [Related]
8. Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors.
Wadhwa P; Jain P; Jadhav HR
Curr Top Med Chem; 2020; 20(17):1522-1534. PubMed ID: 32416693
[TBL] [Abstract][Full Text] [Related]
9. Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders.
Verma MK; Goel R; Krishnadas N; Nemmani KVS
Expert Opin Ther Targets; 2018 Jul; 22(7):615-628. PubMed ID: 29911915
[TBL] [Abstract][Full Text] [Related]
10. Activation of AKT/GSK3β pathway by TDZD-8 attenuates kainic acid induced neurodegeneration but not seizures in mice.
Bhowmik M; Khanam R; Saini N; Vohora D
Neurotoxicology; 2015 Jan; 46():44-52. PubMed ID: 25453207
[TBL] [Abstract][Full Text] [Related]
11. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
Dokken BB; Sloniger JA; Henriksen EJ
Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Wnt/β-catenin pathway in neurodegenerative diseases: recent approaches and current challenges.
Serafino A; Giovannini D; Rossi S; Cozzolino M
Expert Opin Drug Discov; 2020 Jul; 15(7):803-822. PubMed ID: 32281421
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.
Wagman AS; Johnson KW; Bussiere DE
Curr Pharm Des; 2004; 10(10):1105-37. PubMed ID: 15078145
[TBL] [Abstract][Full Text] [Related]
14. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.
Gao C; Hölscher C; Liu Y; Li L
Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.
Beurel E; Grieco SF; Jope RS
Pharmacol Ther; 2015 Apr; 148():114-31. PubMed ID: 25435019
[TBL] [Abstract][Full Text] [Related]
16. GSK3 and miRNA in neural tissue: From brain development to neurodegenerative diseases.
Gizak A; Duda P; Pielka E; McCubrey JA; Rakus D
Biochim Biophys Acta Mol Cell Res; 2020 Jul; 1867(7):118696. PubMed ID: 32165184
[TBL] [Abstract][Full Text] [Related]
17. GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer.
Silva-García O; Cortés-Vieyra R; Mendoza-Ambrosio FN; Ramírez-Galicia G; Baizabal-Aguirre VM
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339170
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
Jope RS; Roh MS
Curr Drug Targets; 2006 Nov; 7(11):1421-34. PubMed ID: 17100582
[TBL] [Abstract][Full Text] [Related]
19. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases.
Takenouchi T; Sekiyama K; Sekigawa A; Fujita M; Waragai M; Sugama S; Iwamaru Y; Kitani H; Hashimoto M
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):91-6. PubMed ID: 20143170
[TBL] [Abstract][Full Text] [Related]
20. Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.
Medina M; Avila J
Expert Rev Neurother; 2013 May; 13(5):495-503. PubMed ID: 23621307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
